Aktuellt
SENASTE
Q2 marked a strong recovery from a weak Q1 and showed sales growth of 59% y/y, with both direct sales and sales to partners contributing. We have previously argued for 2022 to be a year of execution on high growth ambitions. Uncertainty from potential external headwinds remains, but SyntheticMR does not see any problems on the horizon for now, and Q2, in our view, confirmed our belief of continued strong growth through the year.
LÄS MER
